ClinicalTrials.gg
RecruitingNCT07059520PRESSUREUpdated Jul 31, 2025

Translesional PRESSURE Measurements to Assess Clinical Relevance of a Mesenteric Artery Stenosis (PRESSURE-study)

An observational study in Chronic Mesenteric Ischemia and Ischemia, Mesenteric, sponsored by Erasmus Medical Center. Recruiting at 3 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Erasmus Medical Center · Observational

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
125
Ages
18 Years and older
Sex
All
01

Study summary

Chronic mesenteric ischemia (CMI) is an incapacitating disease with a vast impact on quality of life due to severe abdominal pain after a meal, resulting in fear of eating and subsequent weight loss. CMI is most frequently caused by an atherosclerotic mesenteric artery stenosis, which is a frequent finding in the general population (6-29%). CMI is less prevalent due to an extensive collateral circulation protecting the gut against ischemia.

Hence, imaging alone cannot be relied upon, making the diagnosis of CMI challenging. Treatment decisions for atherosclerotic CMI are currently based on history, stenosis severity on imaging, and signs of mesenteric ischemia during a functional test. Yet, sufficiency of the collateral circulation cannot be assessed, resulting in substantial failure to recover from symptoms after stentplacement (27-31% in single vessel disease), unnecessary complications, and avoidable healthcare expenses. A retrospective cohort study by van Dijk et al. reports that intra-arterial pressure measurements could predict clinical success of mesenteric artery revascularization with an 86% sensitivity and 83% specificity, indicating that mesenteric artery pressure measurements could be a highly desired and promising tool for the assessment of hemodynamic and clinical relevance of a mesenteric artery stenosis. Which is sensible, since pressure gradients will only occur when both a severe mesenteric artery stenosis and an insufficient collateral circulation are present. Another advantages of pressure measurements is the ability to simulate the postprandial physiology, using nitroglycerin, enabling measurements when mesenteric blood flow is maximal. Intra-arterial pressure measurements are currently the most promising tool to guide clinical decision making in patients with suspected CMI and could result in major improvements in quality of life by improving clinical success of mesenteric artery revascularization, decreasing complication risks and decreasing healthcare costs by facilitating allocation of health care resources to those patients actually benefitting from treatment.

Read the detailed description

Chronic mesenteric ischemia (CMI) is an incapacitating disease with a vast impact on quality of life due to severe abdominal pain after a meal, resulting in fear of eating and subsequent severe weight loss. CMI has an incidence of 9.2 per 100,000, which increases with age to up to 44.3 per 100,000 in persons of ≥80 years. These incidence rates are higher than the incidence rates of other more well-known diseases, such as esophageal cancer (4.3 per 100,000) or ruptured abdominal aortic aneurysms (7.0 per 100,000), and even approximates the incidence of Crohn's disease (10.9 per 100,000). The prevalence of atherosclerotic mesenteric artery stenosis, the leading cause of CMI, is even higher (6-29%). An extensive collateral circulation protects the gut against ischemia in the majority of patients. Hence, not all mesenteric artery stenoses result in CMI and only those stenoses that are hemodynamically significant should be treated. Treatment decisions for atherosclerotic CMI are currently based on history, stenosis severity on imaging, and signs of mesenteric ischemia during a functional test. However, sufficiency of the collateral circulation cannot be assessed, resulting in substantial failure of patient-reported symptom relief after stent placement (27-31% in single vessel disease), unnecessary complications and avoidable healthcare expenses.

The Dutch Mesenteric Ischemia Study group (DMIS) consists of experts in the field of CMI and aims to improve both the quality of care and the quality of life of CMI patients by initiating and designing studies to provide patient-centered and evidence-based solutions to pending challenges in the field of CMI. In recent years the DMIS has been searching for a reliable tool to assess hemodynamic significance of a mesenteric artery stenosis, while accounting for the collateral circulation, in order to guide treatment decisions and avoid clinically unbeneficial revascularization procedures. In a retrospective study flow velocities were increased in the unaffected mesenteric artery when either the CA or SMA were stenosed. The increased blood flow in the unaffected vessel could indicate a well-functioning collateral network where blood flow is rerouted to prevent chronic mesenteric ischemia.

Another retrospective cohort study reports that intra-arterial pressure measurements, using a 4Fr catheter, could predict clinical success of mesenteric artery revascularization with an 86% sensitivity and 83% specificity. In this retrospective study, pressure gradients were obtained after administration of a vasodilator. With these pressure measurements, the Pd/Pa ratio and the fractional flow reserve (FFR) were measured. The Pd/Pa ratio is the pressure distal to the stenosis divided by pressure in the aorta and the FFR is the Pd/Pa ratio under hyperemic conditions, after administration of a vasodilator. Mesenteric artery pressure measurements could be a promising tool for the assessment of hemodynamic and clinical relevance of mesenteric artery stenosis, since pressure gradients will only occur in mesenteric arteries with a severe stenosis and an insufficient collateral circulation.

The previously performed retrospective study yielded promising results, but had some methodological limitations. Pressure measurements in the conducted study were only obtained in a subset of CMI patients by the decision of the interventional radiologist, with pressure measurements in general only performed when the radiologist was in doubt about the significance of the stenosis. This could have potentially led to selection bias and makes reproducibility of this study difficult to the general population of CMI patients as a whole. In the proposed study, the investigator will perform pressure measurements in the general population of CMI patients with a consensus diagnosis of CMI who are scheduled for endovascular treatment, hypothesizing that stenosis grade (%) alone cannot predict hemodynamic significance accurately. By obtaining pressure measurements in all CMI patients, including borderline, high-grade stenoses and occlusions, the investigators aim to evaluate the (in)sufficiency of the mesenteric collateral network by measuring pressure gradients over the stenotic lesion. The investigators hope such pressure gradients can predict clinical treatment success for all CMI patients. If positive results are obtained in this study, the investigators hope these measurements can serve as a decision-making tool in suspected CMI patients (to stent or not to stent).

In an in-vitro study (currently under submission) in which postprandial states in the superior mesenteric artery (SMA) and celiac artery (CA) were simulated, pressure measurements were obtained using a 4Fr macrocatheter, microcatheter and pressure wire. It showed that especially for a stenosis ≥75% or a longer stenosis, the 4Fr catheter tended to overestimate the fractional flow reserve (FFR) when compared to the microcatheter, due to partial obstruction of the residual vessel lumen by the relatively large size of the 4Fr catheter compared to microcatheter or pressure wire. Taking this into consideration together with a wider applicability and lower costs, they recommended the microcatheter for clinical use.

In addition, intra-arterial stress pressure measurements with a vasodilator (nitroglycerin) could make the measurements more reliable, since intestinal ischemia mainly occurs after a meal when blood flow is maximal and expected to increase by 30-150%. Ischemia in CMI is thus temporary and this dynamic process causes false negative tests when blood flow is not maximal. Intra-arterial injection of nitroglycerin is able to increase the mesenteric blood flow, thereby challenging the compensatory capacity of the mesenteric circulation and predicting clinical success of revascularization. In a retrospective study, the Pd/Pa ratio after administration of nitroglycerin yielded the most promising results with the highest sensitivity and specificity.

Intra-arterial nitroglycerin is already routinely administered during coronary angiography for cardiology patients. Moreover, intra-arterial vasodilators can be used as treatment for acute nonocclusive mesenteric ischemia (NOMI). In the retrospective study, no adverse events related to intra-arterial nitroglycerin had occurred, making intra-arterial pressure measurements a safe and useful tool to guide future treatment decisions (to stent or not to stent). Successful implementation of this strategy could result in a substantial reduction of the number of unbeneficial mesenteric artery revascularizations, thereby avoiding potential loss of quality of life due to complications and a reduction of healthcare expenses.

Intra-arterial pressure measurements could also enlighten the debate on other topics regarding mesenteric artery revascularization. Current guidelines define a stenosis severity of ≥70% as significant in single vessel disease, while a ≥50% stenosis of the SMA is considered significant when accompanied by a ≥70% stenosis of the CA. These definitions are mainly based on expert opinion and cannot be supported with solid evidence. Intra-arterial pressure measurements could prove whether use of the current definitions should be continued or whether the definitions should be revised. The latter seems more probable, since hemodynamic significance of a mesenteric artery stenosis depends on a combination of both stenosis severity and the compensatory capacity of the collateral circulation, which cannot be assessed on computed tomography angiography (CTA) or magnetic resonance angiography (MRA). A future definition could state that pressure measurements are mandatory in all patients to confirm that revascularization is indicated.

The current recommendation to revascularize both mesenteric arteries in patients with multivessel disease of CA and SMA is another example of a recommendation that could be revised based on results of intra-arterial pressure measurements. Pressure measurements could identify those patients in whom stenting of both vessels is indicated. Measurement of normal pressures in the CA, after SMA revascularization, suggests that the CA stenosis is no longer hemodynamically relevant. Revascularization of the CA is in this case no longer indicated and both the possible complications of CA revascularization and the unneeded expenses of CA stenting can be avoided.

Intra-arterial pressure measurements are currently the most promising tool to guide clinical decision-making in patients with suspected CMI. Implementation of pressure measurements could result in major improvements in quality of life by tailoring treatment to the patient's needs, thereby improving the clinical success of mesenteric artery revascularization and decreasing complication risks. This will ultimately result in a reduction of population-based healthcare costs by facilitating allocation of healthcare resources to those patients actually benefitting from treatment. The DMIS has designed a multicenter study to determine the predictive value of intra-arterial pressure measurements after administration of nitroglycerin using a microcatheter to predict clinical success of mesenteric artery revascularization, to set an optimal cut-off for the guidance of treatment decisions, and to determine cost-effectiveness of future clinical implementation of intra-arterial pressure measurements.

Primary Objective:

- To assess the predictive performance of the Pd/Pa ratio after administration of a vasodilator to predict the clinical success of mesenteric artery stenting

02

Conditions studied

  • Chronic Mesenteric Ischemia
  • Ischemia, Mesenteric

Browse trials for

Keywords

  • chronic mesenteric ischemia
  • Pd/Pa ratio
  • FFR
  • Collateral circulation
03

In context

Mesenteric Ischemia

40 studies on the registry are indexed under Mesenteric Ischemia; 14 are open to participants now.

This study's planned enrollment of 125 is below the median of 154 across 26 observational studies indexed under Mesenteric Ischemia.

Browse Mesenteric Ischemia studies →

Lead sponsor

Erasmus Medical Center is the lead sponsor of 478 studies on the registry; 183 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients undergoing an interventional or diagnostic endovascular procedure of the mesenteric arteries are eligible for inclusion.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients with chronic mesenteric ischemia (CMI) and scheduled for endovascular procedure of the mesenteric arteries
  • Age ≥18 years of age
  • Patients who gave

Exclusion criteria

Exclusion Criteria:

  • Patients presenting with acute mesenteric ischemia
  • Common origin of the SMA and CA (normal variant)
  • Patients unable to give
  • Pregnancy
  • Other criteria the physician considers not compatible with this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
125 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Patients with a consensus diagnosis of chronic mesenteric ischemia

    Patients with a consensus diagnosis of chronic mesenteric ischemia who are scheduled for endovascular treatment

06

What researchers measure

Primary outcomes

  1. Pd/Pa ratio after administration of a vasodilator and its association with clinical success of mesenteric artery stenting

    Pd/Pa ratio after administration of a vasodilator and its association with clinical success of mesenteric artery stenting

    Time frame: From enrollment to 3 months after treatment

07

Study locations

2 of 3 sites recruiting
08

References and documents

Publications

  • van Petersen AS, Kolkman JJ, Meerwaldt R, Huisman AB, van der Palen J, Zeebregts CJ, Geelkerken RH. Mesenteric stenosis, collaterals, and compensatory blood flow. J Vasc Surg. 2014 Jul;60(1):111-9, 119.e1-2. doi: 10.1016/j.jvs.2014.01.063. Epub 2014 Mar 18. PubMed 24650741 ↗
  • Sadiq I, Chamakura S, Siddiqi S, Margey R, Azemi T. Use of fractional flow reserve in the assessment of chronic mesenteric ischemia. Vasc Med. 2014 Jun;19(3):182-188. doi: 10.1177/1358863X14529617. Epub 2014 May 30. PubMed 24879713 ↗
  • Takiguchi T, Nakajima M, Ohbe H, Sasabuchi Y, Matsui H, Fushimi K, Kim S, Yokota H, Yasunaga H. Vasodilator Therapy and Mortality in Nonocclusive Mesenteric Ischemia: A Nationwide Observational Study. Crit Care Med. 2020 May;48(5):e356-e361. doi: 10.1097/CCM.0000000000004255. PubMed 32044841 ↗
  • Twiner MJ, Hennessy J, Wein R, Levy PD. Nitroglycerin Use in the Emergency Department: Current Perspectives. Open Access Emerg Med. 2022 Jul 9;14:327-333. doi: 10.2147/OAEM.S340513. eCollection 2022. PubMed 35847764 ↗
  • Boyer N, Beyer A, Gupta V, Dehghani H, Hindnavis V, Shunk K, Zimmet J, Yeghiazarians Y, Ports T, Boyle A. The effects of intra-arterial vasodilators on radial artery size and spasm: implications for contemporary use of trans-radial access for coronary angiography and percutaneous coronary intervention. Cardiovasc Revasc Med. 2013 Nov-Dec;14(6):321-4. doi: 10.1016/j.carrev.2013.08.009. Epub 2013 Oct 2. PubMed 24095616 ↗
  • Bertrand OF, Rao SV, Pancholy S, Jolly SS, Rodes-Cabau J, Larose E, Costerousse O, Hamon M, Mann T. Transradial approach for coronary angiography and interventions: results of the first international transradial practice survey. JACC Cardiovasc Interv. 2010 Oct;3(10):1022-31. doi: 10.1016/j.jcin.2010.07.013. PubMed 20965460 ↗
  • Pillai AK, Kalva SP, Hsu SL, Walker TG, Silberzweig JE, Annamalai G, Baerlocher MO, Mitchell JW, Midia M, Nikolic B, Dariushnia SR; Society of Interventional Radiology Standards of Practice Committee. Quality Improvement Guidelines for Mesenteric Angioplasty and Stent Placement for the Treatment of Chronic Mesenteric Ischemia. J Vasc Interv Radiol. 2018 May;29(5):642-647. doi: 10.1016/j.jvir.2017.11.024. Epub 2018 Mar 21. No abstract available. PubMed 29574024 ↗
  • Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10.1093/eurheartj/ehy394. No abstract available. PubMed 30165437 ↗
  • Garcia LA, Carrozza JP Jr. Physiologic evaluation of translesion pressure gradients in peripheral arteries: comparison of pressure wire and catheter-derived measurements. J Interv Cardiol. 2007 Feb;20(1):63-5. doi: 10.1111/j.1540-8183.2007.00213.x. PubMed 17300406 ↗
  • Imbesi SG, Kerber CW. Pressure Measurements across Vascular Stenoses. Practice and Pitfalls. Interv Neuroradiol. 1999 Jun 30;5(2):139-44. doi: 10.1177/159101999900500205. Epub 2001 May 15. PubMed 20670502 ↗
  • Moneta GL, Yeager RA, Dalman R, Antonovic R, Hall LD, Porter JM. Duplex ultrasound criteria for diagnosis of splanchnic artery stenosis or occlusion. J Vasc Surg. 1991 Oct;14(4):511-8; discussion 518-20. PubMed 1920649 ↗
  • Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae. PubMed 15273542 ↗
  • Bjorck M, Koelemay M, Acosta S, Bastos Goncalves F, Kolbel T, Kolkman JJ, Lees T, Lefevre JH, Menyhei G, Oderich G, Esvs Guidelines Committee, Kolh P, de Borst GJ, Chakfe N, Debus S, Hinchliffe R, Kakkos S, Koncar I, Sanddal Lindholt J, Vega de Ceniga M, Vermassen F, Verzini F, Document Reviewers, Geelkerken B, Gloviczki P, Huber T, Naylor R. Editor's Choice - Management of the Diseases of Mesenteric Arteries and Veins: Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2017 Apr;53(4):460-510. doi: 10.1016/j.ejvs.2017.01.010. No abstract available. PubMed 28359440 ↗
  • van Dijk LJD, Harki J, van Noord D, Verhagen HJM, Kolkman JJ, Geelkerken RH, Bruno MJ, Moelker A; Dutch Mesenteric Ischemia Study group (DMIS). Covered stents versus Bare-metal stents in chronic atherosclerotic Gastrointestinal Ischemia (CoBaGI): study protocol for a randomized controlled trial. Trials. 2019 Aug 20;20(1):519. doi: 10.1186/s13063-019-3609-8. PubMed 31429792 ↗
  • Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, Swinburn P, Busschbach J. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013 Sep;22(7):1717-27. doi: 10.1007/s11136-012-0322-4. Epub 2012 Nov 25. PubMed 23184421 ↗
  • Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002 Mar;21(2):271-92. doi: 10.1016/s0167-6296(01)00130-8. PubMed 11939242 ↗
  • Mensink PB, Moons LM, Kuipers EJ. Chronic gastrointestinal ischaemia: shifting paradigms. Gut. 2011 May;60(5):722-37. doi: 10.1136/gut.2009.199695. Epub 2010 Nov 29. PubMed 21115543 ↗
  • van Dijk LJD, Terlouw LG, van Noord D, Bijdevaate DC, Bruno MJ, Moelker A. Endovascular Pressure Measurements to Assess the Functional Severity of Mesenteric Arterial Stenoses. J Vasc Interv Radiol. 2020 Mar;31(3):430-437. doi: 10.1016/j.jvir.2019.10.019. Epub 2020 Jan 29. PubMed 32007405 ↗
  • van Dijk LJ, van Noord D, de Vries AC, Kolkman JJ, Geelkerken RH, Verhagen HJ, Moelker A, Bruno MJ. Clinical management of chronic mesenteric ischemia. United European Gastroenterol J. 2019 Mar;7(2):179-188. doi: 10.1177/2050640618817698. Epub 2018 Dec 4. PubMed 31080602 ↗
  • van Petersen AS, Kolkman JJ, Gerrits DG, van der Palen J, Zeebregts CJ, Geelkerken RH; Dutch Mesenteric Ischemia Study Group. Clinical significance of mesenteric arterial collateral circulation in patients with celiac artery compression syndrome. J Vasc Surg. 2017 May;65(5):1366-1374. doi: 10.1016/j.jvs.2016.11.052. Epub 2017 Mar 2. PubMed 28259570 ↗
  • van den Heuvel TRA, Jeuring SFG, Zeegers MP, van Dongen DHE, Wolters A, Masclee AAM, Hameeteman WH, Romberg-Camps MJL, Oostenbrug LE, Pierik MJ, Jonkers DM. A 20-Year Temporal Change Analysis in Incidence, Presenting Phenotype and Mortality, in the Dutch IBDSL Cohort-Can Diagnostic Factors Explain the Increase in IBD Incidence? J Crohns Colitis. 2017 Oct 1;11(10):1169-1179. doi: 10.1093/ecco-jcc/jjx055. PubMed 28430884 ↗
  • Howard DP, Banerjee A, Fairhead JF, Handa A, Silver LE, Rothwell PM; Oxford Vascular Study. Age-specific incidence, risk factors and outcome of acute abdominal aortic aneurysms in a defined population. Br J Surg. 2015 Jul;102(8):907-15. doi: 10.1002/bjs.9838. Epub 2015 May 7. PubMed 25955556 ↗
  • Terlouw LG, Verbeten M, van Noord D, Brusse-Keizer M, Beumer RR, Geelkerken RH, Bruno MJ, Kolkman JJ; Dutch Mesenteric Ischemia Study Group. The Incidence of Chronic Mesenteric Ischemia in the Well-Defined Region of a Dutch Mesenteric Ischemia Expert Center. Clin Transl Gastroenterol. 2020 Aug;11(8):e00200. doi: 10.14309/ctg.0000000000000200. PubMed 32955192 ↗
  • Blauw JTM, Pastoors HAM, Brusse-Keizer M, Beuk RJ, Kolkman JJ, Geelkerken RH, For The Dutch Mesenteric Ischemia Study Group. The Impact of Revascularisation on Quality of Life in Chronic Mesenteric Ischemia. Can J Gastroenterol Hepatol. 2019 Nov 12;2019:7346013. doi: 10.1155/2019/7346013. eCollection 2019. PubMed 31781520 ↗
  • Alahdab F, Arwani R, Pasha AK, Razouki ZA, Prokop LJ, Huber TS, Murad MH. A systematic review and meta-analysis of endovascular versus open surgical revascularization for chronic mesenteric ischemia. J Vasc Surg. 2018 May;67(5):1598-1605. doi: 10.1016/j.jvs.2017.12.046. Epub 2018 Mar 20. PubMed 29571626 ↗
  • Terlouw LG, Moelker A, Abrahamsen J, Acosta S, Bakker OJ, Baumgartner I, Boyer L, Corcos O, van Dijk LJ, Duran M, Geelkerken RH, Illuminati G, Jackson RW, Karkkainen JM, Kolkman JJ, Lonn L, Mazzei MA, Nuzzo A, Pecoraro F, Raupach J, Verhagen HJ, Zech CJ, van Noord D, Bruno MJ. European guidelines on chronic mesenteric ischaemia - joint United European Gastroenterology, European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Gastrointestinal and Abdominal Radiology, Netherlands Association of Hepatogastroenterologists, Hellenic Society of Gastroenterology, Cardiovascular and Interventional Radiological Society of Europe, and Dutch Mesenteric Ischemia Study group clinical guidelines on the diagnosis and treatment of patients with chronic mesenteric ischaemia. United European Gastroenterol J. 2020 May;8(4):371-395. doi: 10.1177/2050640620916681. Epub 2020 Apr 16. PubMed 32297566 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Jul 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Jul 10, 2025
StartActual
Apr 1, 2025
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07059520
Responsible party
Kay Pieterman (Radiologist, MD, PhD, Erasmus Medical Center) — Principal investigator
First posted
Jul 10, 2025
Start date
Apr 1, 2025
Primary completion
Jul 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Jul 31, 2025

Study contacts

Eva Karina Bocharewicz, PhD Candidate
Contact
e.bocharewicz@erasmusmc.nl
+31652216196

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion